Agency Forms Undergoing Paperwork Reduction Act Review, 41472-41473 [2021-16377]
Download as PDF
<![CDATA[
41472
Federal Register / Vol. 86, No. 145 / Monday, August 2, 2021 / Notices
during the 80-day comment period for
the proposed interim decision in the
discussion for paraquat. Comments from
the 80-day comment period that were
received may or may not have affected
the Agency’s interim decision. Pursuant
to 40 CFR 155.58(c), the registration
review case docket for paraquat will
remain open until all actions required in
the interim decision have been
completed.
Background on the registration review
program is provided at: https://
www.epa.gov/pesticide-reevaluation.
Authority: 7 U.S.C. 136 et seq.
Radiocommunication Conference
(WRC–23).
In accordance with the Federal
Advisory Committee Act, Public Law
92–463, as amended, this notice advises
interested persons of the IWG–3 and
IWG–4 of the WRC–23 Advisory
Committee scheduled meetings. The
Commission’s WRC–23 website
(www.fcc.gov/wrc-23) contains the latest
information on all scheduled meetings,
meeting agendas, and WRC–23 Advisory
Committee matters.
The revised schedule of IWG–3 and
IWG–4 meetings are as follows:
WRC–23 Advisory Committee
Dated: July 26, 2021.
Mary Reaves,
Acting Director, Pesticide Re-Evaluation
Division, Office of Pesticide Programs.
Schedule of Meetings of Informal
Working Groups 3 and 4
Informal Working Group 3: Space
Services
[FR Doc. 2021–16344 Filed 7–30–21; 8:45 am]
BILLING CODE 6560–50–P
Contacts
Chair—Zachary Rosenbaum,
zachary.rosenbaum@ses.com,
telephone: (814) 233–7373
Vice Chair—Vacant
FEDERAL COMMUNICATIONS
COMMISSION
[IB Docket No. 16–185; DA 21–898; FRS
40705]
FCC Representatives
Informal Working Group 3 and Informal
Working Group 4 of the World
Radiocommunication Conference
Advisory Committee Revise Their
Meeting Schedules
Federal Communications
Commission.
ACTION: Notice.
AGENCY:
This notice advises interested
persons that Informal Working Group 3
(IWG–3) and Informal Working Group 4
(IWG–4) of the 2023 World
Radiocommunication Conference
Advisory Committee (WRC–23 Advisory
Committee) have scheduled meetings as
set forth below. The meetings are open
to the public.
DATES: IWG–4: Wednesday, September
1, 2021 (11:00 a.m.–1:00 p.m. EDT);
IWG–3: Wednesday, September 1, 2021
(1:00 p.m.–3:00 p.m. EDT).
ADDRESSES: The meetings will be held
virtually.
SUMMARY:
khammond on DSKJM1Z7X2PROD with NOTICES
FOR FURTHER INFORMATION CONTACT:
Dante Ibarra, Designated Federal
Official, World Radiocommunication
Conference Advisory Committee, FCC
International Bureau, Global Strategy
and Negotiation Division, at
Dante.Ibarra@fcc.gov, (202) 418–0610 or
WRC-23@fcc.gov.
SUPPLEMENTARY INFORMATION: The FCC
established the Advisory Committee to
provide advice, technical support and
recommendations relating to the
preparation of United States proposals
and positions for the 2023 World
VerDate Sep<11>2014
17:21 Jul 30, 2021
Jkt 253001
Clay DeCell, clay.decell@fcc.gov,
telephone: (202) 418–0803
Kathyrn Medley, kathyrn.medley@
fcc.gov, telephone: (202) 418–1211
Eric Grodsky, eric.grodsky@fcc.gov,
telephone: (202) 418–0563
Dante Ibarra, dante.ibarra@fcc.gov,
telephone: (202) 418–0610
IWG–3—Meeting
Date: Wednesday, September 1, 2021
Time: 1:00 p.m.–3:00 p.m. EDT
WebEx meeting number (access code):
199 562 2904
WebEx meeting password: qPdpJJJR232
Join by phone: +1–415–527–5035 US
Toll
Informal Working Group 4: Regulatory
Issues
Contacts
Chair – David Goldman,
david.goldman@spacex.com,
telephone: (202) 649–2641
Vice Chair—Giselle Creeser,
giselle.creeser@intelsat.com,
telephone: (703) 559–7851
FCC Representatives
Dante Ibarra, dante.ibarra@fcc.gov,
telephone: (202) 418–0610
Clay DeCell, clay.decell@fcc.gov,
telephone: (202) 418–0803
IWG–4—Meeting
Date: Wednesday, September 1, 2021
Time: 11:00 a.m.–1:00 p.m. EDT
WebEx meeting number (access code):
199 742 9498
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
WebEx meeting password:
UdrMTgz7m53
Join by phone: +1–415–527–5035 US
Toll
Federal Communications Commission.
Troy Tanner,
Deputy Chief, International Bureau.
[FR Doc. 2021–16353 Filed 7–30–21; 8:45 am]
BILLING CODE 6712–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30Day–21–21EE]
Agency Forms Undergoing Paperwork
Reduction Act Review
In accordance with the Paperwork
Reduction Act of 1995, the Centers for
Disease Control and Prevention (CDC)
has submitted the information
collection request titled Integrated Viral
Hepatitis Surveillance and Prevention
Funding for Health Departments (CDC–
RFA–PS21–2103) to the Office of
Management and Budget (OMB) for
review and approval. CDC previously
published a ‘‘Proposed Data Collection
Submitted for Public Comment and
Recommendations’’ notice on April 16,
2021 to obtain comments from the
public and affected agencies. CDC
received two comments related to the
previous notice. This notice serves to
allow an additional 30 days for public
and affected agency comments.
CDC will accept all comments for this
proposed information collection project.
The Office of Management and Budget
is particularly interested in comments
that:
(a) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
(b) Evaluate the accuracy of the
agencies estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and
clarity of the information to be
collected;
(d) Minimize the burden of the
collection of information on those who
are to respond, including, through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses; and
E:\FR\FM\02AUN1.SGM
02AUN1
41473
Federal Register / Vol. 86, No. 145 / Monday, August 2, 2021 / Notices
(e) Assess information collection
costs.
To request additional information on
the proposed project or to obtain a copy
of the information collection plan and
instruments, call (404) 639–7570.
Comments and recommendations for the
proposed information collection should
be sent within 30 days of publication of
this notice to www.reginfo.gov/public/
do/PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function. Direct written
comments and/or suggestions regarding
the items contained in this notice to the
Attention: CDC Desk Officer, Office of
Management and Budget, 725 17th
Street NW, Washington, DC 20503 or by
fax to (202) 395–5806. Provide written
comments within 30 days of notice
publication.
Proposed Project
Integrated Viral Hepatitis Surveillance
and Prevention Funding for Health
Departments (CDC–RFA–PS21–2103)—
New—National Center for HIV/AIDS,
Viral Hepatitis, STD, and TB Prevention
(NCHHSTP), Centers for Disease Control
and Prevention (CDC).
Background and Brief Description
In 2021, CDC is implementing
activities under a new cooperative
agreement Integrated Viral Hepatitis
Surveillance and Prevention Funding
for Health Departments (CDC–RFA–
PS21–2103). Tools exist to prevent new
cases of hepatitis A, hepatitis B, and
hepatitis C, to treat people living with
hepatitis B, and to cure people living
with hepatitis C. Yet, new cases of viral
hepatitis (VH) continue to rise, many
people infected with VH remain
undiagnosed, and far too many VHrelated deaths occur in the US each
year. The purpose of the activities under
this new cooperative agreement is to
enable states to collect data to evaluate
disease burden and trends, and to
analyze and disseminate that data to
develop or refine recommendations,
policies, and practices that will
ultimately reduce the burden of VH in
their jurisdictions. The goals of the
activities are to reduce new VH
infections, VH-related morbidity and
mortality, and VH-related disparities,
and to establish comprehensive national
VH surveillance, which are in
accordance with the Division of Viral
Hepatitis 2025 Strategic Plan.
The activities of the new cooperative
agreement are divided into two
components (Component 1:
Surveillance, and Component 2:
Prevention), containing six strategies:
1.1, develop, implement, and maintain
a plan to rapidly detect and respond to
outbreaks for hepatitis A, B, and C; 1.2,
collect, analyze, interpret, and
disseminate data to characterize trends,
and implement public health
interventions for hepatitis A, acute
hepatitis B and acute and chronic
hepatitis C; 1.3 (contingent on available
funding), collect, analyze, interpret, and
disseminate data to characterize trends
and implement public health
interventions for chronic hepatitis B and
perinatal hepatitis C; 2.1, support VH
elimination planning and surveillance,
and maximize access to testing,
treatment, and prevention; 2.2
Type of respondents
Health
Health
Health
Health
Health
Health
Departments
Departments
Departments
Departments
Departments
Departments
(contingent on available funding),
increase access to HCV and HBV testing
and referral to care in high-impact
settings; and 2.3 (contingent on
available funding), improve access to
services preventing VH among persons
who inject drugs. Contingent on
funding, an optional component
(Component 3: Special Projects) will
support improved access to prevention,
diagnosis, and treatment of viral,
bacterial and fungal infections related to
drug use in settings disproportionately
affected by drug use.
Viral hepatitis case surveillance data
will be collected per each jurisdiction’s
usual mechanism using variables that
have been approved by OMB separately
(OMB Control No. 0920–0728).
Performance measures will be
monitored to assess recipient
performance, including quality of data,
effective program implementation, and
accountability of funds. Data collection
via the Annual Performance Report will
be used for program accountability and
to inform performance improvement.
Outbreak reporting will also be
submitted throughout the year. These
data, which complement case data as
another key component of national viral
hepatitis surveillance, are critical to
determining both the level of viral
hepatitis activity within a jurisdiction as
well as the effectiveness of each
jurisdiction’s approach to cluster and
outbreak response.
CDC requests approval for an
estimated 240 annual burden hours.
There is no cost to respondents other
than their time.
Estimated Annualized Burden Hours
Number of
respondents
Form name
.......................................
.......................................
.......................................
.......................................
.......................................
.......................................
APR: Component 1 ..........................................................................
APR: Component 2 ..........................................................................
APR: Component 3 ..........................................................................
Initial Outbreak Report Form ............................................................
Outbreak Summary Report Form .....................................................
Acute Viral Hepatitis Case Reporting ...............................................
59
59
14
59
59
59
khammond on DSKJM1Z7X2PROD with NOTICES
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
[FR Doc. 2021–16377 Filed 7–30–21; 8:45 am]
BILLING CODE 4163–18–P
VerDate Sep<11>2014
21:39 Jul 30, 2021
Jkt 253001
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
E:\FR\FM\02AUN1.SGM
02AUN1
Number of
responses per
respondent
1
1
1
2
2
1
Average
burden per
response
(in hours)
1
1
1
20/60
20/60
30/60
]]>Agencies
[Federal Register Volume 86, Number 145 (Monday, August 2, 2021)]
[Notices]
[Pages 41472-41473]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-16377]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[30Day-21-21EE]
Agency Forms Undergoing Paperwork Reduction Act Review
In accordance with the Paperwork Reduction Act of 1995, the Centers
for Disease Control and Prevention (CDC) has submitted the information
collection request titled Integrated Viral Hepatitis Surveillance and
Prevention Funding for Health Departments (CDC-RFA-PS21-2103) to the
Office of Management and Budget (OMB) for review and approval. CDC
previously published a ``Proposed Data Collection Submitted for Public
Comment and Recommendations'' notice on April 16, 2021 to obtain
comments from the public and affected agencies. CDC received two
comments related to the previous notice. This notice serves to allow an
additional 30 days for public and affected agency comments.
CDC will accept all comments for this proposed information
collection project. The Office of Management and Budget is particularly
interested in comments that:
(a) Evaluate whether the proposed collection of information is
necessary for the proper performance of the functions of the agency,
including whether the information will have practical utility;
(b) Evaluate the accuracy of the agencies estimate of the burden of
the proposed collection of information, including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and clarity of the information to
be collected;
(d) Minimize the burden of the collection of information on those
who are to respond, including, through the use of appropriate
automated, electronic, mechanical, or other technological collection
techniques or other forms of information technology, e.g., permitting
electronic submission of responses; and
[[Page 41473]]
(e) Assess information collection costs.
To request additional information on the proposed project or to
obtain a copy of the information collection plan and instruments, call
(404) 639-7570. Comments and recommendations for the proposed
information collection should be sent within 30 days of publication of
this notice to www.reginfo.gov/public/do/PRAMain. Find this particular
information collection by selecting ``Currently under 30-day Review--
Open for Public Comments'' or by using the search function. Direct
written comments and/or suggestions regarding the items contained in
this notice to the Attention: CDC Desk Officer, Office of Management
and Budget, 725 17th Street NW, Washington, DC 20503 or by fax to (202)
395-5806. Provide written comments within 30 days of notice
publication.
Proposed Project
Integrated Viral Hepatitis Surveillance and Prevention Funding for
Health Departments (CDC-RFA-PS21-2103)--New--National Center for HIV/
AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP), Centers for
Disease Control and Prevention (CDC).
Background and Brief Description
In 2021, CDC is implementing activities under a new cooperative
agreement Integrated Viral Hepatitis Surveillance and Prevention
Funding for Health Departments (CDC-RFA-PS21-2103). Tools exist to
prevent new cases of hepatitis A, hepatitis B, and hepatitis C, to
treat people living with hepatitis B, and to cure people living with
hepatitis C. Yet, new cases of viral hepatitis (VH) continue to rise,
many people infected with VH remain undiagnosed, and far too many VH-
related deaths occur in the US each year. The purpose of the activities
under this new cooperative agreement is to enable states to collect
data to evaluate disease burden and trends, and to analyze and
disseminate that data to develop or refine recommendations, policies,
and practices that will ultimately reduce the burden of VH in their
jurisdictions. The goals of the activities are to reduce new VH
infections, VH-related morbidity and mortality, and VH-related
disparities, and to establish comprehensive national VH surveillance,
which are in accordance with the Division of Viral Hepatitis 2025
Strategic Plan.
The activities of the new cooperative agreement are divided into
two components (Component 1: Surveillance, and Component 2:
Prevention), containing six strategies: 1.1, develop, implement, and
maintain a plan to rapidly detect and respond to outbreaks for
hepatitis A, B, and C; 1.2, collect, analyze, interpret, and
disseminate data to characterize trends, and implement public health
interventions for hepatitis A, acute hepatitis B and acute and chronic
hepatitis C; 1.3 (contingent on available funding), collect, analyze,
interpret, and disseminate data to characterize trends and implement
public health interventions for chronic hepatitis B and perinatal
hepatitis C; 2.1, support VH elimination planning and surveillance, and
maximize access to testing, treatment, and prevention; 2.2 (contingent
on available funding), increase access to HCV and HBV testing and
referral to care in high-impact settings; and 2.3 (contingent on
available funding), improve access to services preventing VH among
persons who inject drugs. Contingent on funding, an optional component
(Component 3: Special Projects) will support improved access to
prevention, diagnosis, and treatment of viral, bacterial and fungal
infections related to drug use in settings disproportionately affected
by drug use.
Viral hepatitis case surveillance data will be collected per each
jurisdiction's usual mechanism using variables that have been approved
by OMB separately (OMB Control No. 0920-0728). Performance measures
will be monitored to assess recipient performance, including quality of
data, effective program implementation, and accountability of funds.
Data collection via the Annual Performance Report will be used for
program accountability and to inform performance improvement. Outbreak
reporting will also be submitted throughout the year. These data, which
complement case data as another key component of national viral
hepatitis surveillance, are critical to determining both the level of
viral hepatitis activity within a jurisdiction as well as the
effectiveness of each jurisdiction's approach to cluster and outbreak
response.
CDC requests approval for an estimated 240 annual burden hours.
There is no cost to respondents other than their time.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Average
Number of Number of burden per
Type of respondents Form name respondents responses per response (in
respondent hours)
----------------------------------------------------------------------------------------------------------------
Health Departments.................... APR: Component 1........ 59 1 1
Health Departments.................... APR: Component 2........ 59 1 1
Health Departments.................... APR: Component 3........ 14 1 1
Health Departments.................... Initial Outbreak Report 59 2 20/60
Form.
Health Departments.................... Outbreak Summary Report 59 2 20/60
Form.
Health Departments.................... Acute Viral Hepatitis 59 1 30/60
Case Reporting.
----------------------------------------------------------------------------------------------------------------
Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Scientific
Integrity, Office of Science, Centers for Disease Control and
Prevention.
[FR Doc. 2021-16377 Filed 7-30-21; 8:45 am]
BILLING CODE 4163-18-P
